Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition).

Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, Fujimoto H, Egawa S, Akaza H, Hara I, Hinotsu S, Kakehi Y, Hasegawa T; Working Group for Creation of Clinical Practice Guidelines for Prostate Cancer, The Japanese Urological Association.

Int J Urol. 2008 Jan;15(1):1-18. doi: 10.1111/j.1442-2042.2007.01959.x. No abstract available.

2.

What your patient needs to know about prostate cancer.

Held-Warmkessel J.

Nursing. 2002 Dec;32(12):36-42; quiz N232. No abstract available.

PMID:
12468938
3.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology.

Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.

PMID:
21056534
4.

[5/7 Prostate cancer in the elderly man].

Mourey L.

Soins Gerontol. 2010 Nov-Dec;(86):45-6. French. No abstract available.

PMID:
21298971
5.

National Comprehensive Cancer Network guidelines for the management of prostate cancer.

Scherr D, Swindle PW, Scardino PT; National Comprehensive Cancer Network.

Urology. 2003 Feb;61(2 Suppl 1):14-24. Review.

PMID:
12667883
6.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
7.

[Clinics in prostate cancer].

Sugimura Y.

Rinsho Byori. 2004 Jul;52(7):604-10. Review. Japanese.

PMID:
15344560
8.

Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.

Akakura K, Tsuji H, Suzuki H, Ichikawa T, Ishikawa H, Okada T, Kamada T, Harada M, Tsujii H, Shimazaki J.

Jpn J Clin Oncol. 2014 Apr;44(4):360-5. doi: 10.1093/jjco/hyu006. Epub 2014 Feb 28.

PMID:
24585931
9.

[Neoadjuvant hormonal therapy for prostate cancer].

Miyakita H.

Nihon Rinsho. 2005 Feb;63(2):309-13. Japanese.

PMID:
15714984
10.

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Horwich A, Parker C, de Reijke T, Kataja V; ESMO Guidelines Working Group.

Ann Oncol. 2013 Oct;24 Suppl 6:vi106-14. doi: 10.1093/annonc/mdt208. Epub 2013 Jun 27. No abstract available.

PMID:
23813930
11.
12.

[Treatment for cancer specifically diagnosed in high-aged population, prostate cancer].

Miki T.

Nihon Ronen Igakkai Zasshi. 2006 Jan;43(1):71-3. Japanese. No abstract available.

PMID:
16521807
13.

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.

McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e39-46. doi: 10.1016/j.ijrobp.2012.08.036. Epub 2012 Oct 23.

14.

Diagnosis and treatment of patients with prostate cancer: the nurse's role.

Turner B.

Nurs Stand. 2007 Jun 6-12;21(39):48-56; quiz 58. Review.

PMID:
17569378
15.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
16.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
17.

[Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].

Salomon L, Ploussard G, Coloby P, Kouri G, Lebret T, Méjean A, Prunet D, Soulié M.

Prog Urol. 2014 May;24(6):367-73. doi: 10.1016/j.purol.2013.10.007. Epub 2013 Nov 15. French.

PMID:
24821560
18.

Prostatic cancer: are we closer to rational treatment selection?

Scher HI.

Curr Opin Oncol. 1992 Jun;4(3):442-54. Review.

PMID:
1379831
19.

Prostate cancer.

Schlegel PN.

Curr Ther Endocrinol Metab. 1994;5:543-50. No abstract available.

PMID:
7535663
20.

Combating prostate cancer.

Garnick MB, Fair WR.

Sci Am. 1998 Dec;279(6):74-83. No abstract available.

PMID:
9828467

Supplemental Content

Support Center